Data presented at the 19th Annual WORLDSymposiumTM 2023

TOKYO, February 22, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical trial evaluating the safety, tolerability and exploratory efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD). The data will be presented during a platform presentation at the 19th Annual WORLDSymposium in Orlando, FL (Poster: #95). AT845 is an investigational adeno-associated virus (AAV) gene replacement therapy designed to deliver a functional human acid alpha-glucosidase (GAA) gene directly in muscle cells in adults with LOPD.

“There is tremendous need for new treatment approaches in progressive, debilitating, genetic diseases like LOPD that move beyond standard of care enzyme replacement therapy (ERT),” said Jordi Díaz-Manera, MD, PhD, Professor of Neuromuscular Disorders and Honorary Consultant Clinical Geneticist for the Newcastle Hospitals NHS Foundation Trust at Newcastle University, UK. “AAV gene therapies have the potential to be a safe and effective approach to delivering a functional GAA gene directly to the muscle tissues in patients with LOPD."

FORTIS is an ongoing multicenter, open-label, ascending dose Phase 1/2 first-in-human clinical trial to determine the safety, tolerability and exploratory efficacy of AT845 in adults with LOPD. As of the September 15th, 2022, data cut-off, four participants received a one-time intravenous infusion of AT845, with two dosed at the 3x1013 vg/kg dose level and two dosed at the 6x1013 vg/kg dose level, with up to 78 weeks of safety follow-up in the clinical trial. Three of the four participants have discontinued ERT following administration of AT845, and their measured functional outcomes have been stable while off ERT for 19, 44, and 51 weeks, respectively. The ongoing evaluation of the dosed participants, including those who discontinued ERT, showed continued stability of disease functional endpoints, including forced vital capacity and the 6-minute walk test. Patient-reported outcomes for fatigue and daily activities (Pompe-specific) also appeared stable.

Each participant’s infusion of AT845 was generally well-tolerated, and most treatment-emergent adverse effects were mild (grade 1) and considered to be unrelated to study treatment. A possible infusion-related reaction occurred in one participant and resolved with oral diphenhydramine and acetaminophen. Three participants developed transient transaminitis and deemed possibly related to AT845. In all cases, the event resolved with modifications to immune suppression. A grade 2 peripheral sensory polyneuropathy event was reported in one participant in the 6x1013 vg/kg cohort, which led to an FDA clinical hold in June 2022. The FDA lifted this clinical hold in January 2023.

“We are excited to share these new findings from the ongoing FORTIS clinical study of AT845. These data, along with our recent announcement of the clinical hold lift of the FORTIS clinical trial, are very positive developments for the program,” said Ha Tran, Executive Medical Director for Astellas. “The preliminary data presented are encouraging. We look forward to continuing the FORTIS clinical trial as we advance towards our goal of developing innovative gene therapies and bringing new potential treatments to patients with high unmet need.”


Click below for a copy of the full press release


Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)